New Drug Awaits FDA Decision Offering Hope for Children With Fatal Hunter Syndrome

Dr. Rachel Mendez MD, Medical Science Writer

✨ Why this is good news

A potential new treatment for a rare, fatal childhood genetic disorder is awaiting FDA approval.

Targets the Untreatable Neurological Decline.Existing treatments cannot cross the blood-brain barrier, leaving cognitive damage unchecked. This new drug is specifically engineered to reach the brain, potentially slowing or preventing devastating neurological symptoms for the first time.
Denali's Drug is a First-in-Class Therapy.Before now, no treatment addressed the root cause of Hunter syndrome inside the central nervous system. Its novel design represents a fundamental shift from managing physical symptoms to targeting the core neurological progression of the disease.
Urgent Advocacy Accelerated the Timeline.The FDA's decision is set for April, a timeline influenced by direct family advocacy. This rapid review process brings a critical therapy to a decision point much sooner than is typical for many rare disease treatments.
Offers a Lifeline to Children Like Rory.For patients facing a terminal diagnosis with limited options, this approval represents concrete hope. It could provide more years of life with preserved cognitive function, directly changing outcomes for affected families.

A novel therapy for the rare and fatal genetic disorder Hunter syndrome faces a critical FDA approval decision in April, offering a potential lifeline to children like six-year-old Rory Jaskulski. The drug, developed by Denali Therapeutics, is designed to cross the blood-brain barrier, addressing the neurological decline that current treatments cannot reach.

Hunter syndrome, or mucopolysaccharidosis II, is caused by the body's inability to produce an enzyme that breaks down specific molecules. These molecules then accumulate, causing severe physical disabilities, cognitive delays, and organ damage. Life expectancy is typically between 10 and 20 years with existing treatments, which manage some physical symptoms but do not halt cognitive deterioration. Rory, a kindergarten student from New Berlin, was diagnosed at age four and is non-verbal.

The investigational drug, DNL310, aims to deliver the needed enzyme directly into the central nervous system. This approach could potentially slow or prevent the progressive neurological aspects of the disease, a breakthrough over current standard care. "It's either this or they're going to die from this disease," said Rory's mother, Kylie Jaskulski, emphasizing the lack of alternatives. The FDA's decision comes after recent rejections of other Hunter syndrome treatments using gene therapy, though Denali's product is a different type of therapy.

The upcoming regulatory verdict carries immense weight for families. Approval would provide a new treatment option where none existed for the disease's cognitive impact. A rejection, however, could mean years of delay. "If this drug does not get approved in April, it won't come in time to save Rory," Kylie Jaskulski noted, highlighting the urgent timeline for many children. The community now watches closely, hoping for a positive outcome that could alter the trajectory of this devastating condition.

With the April 5 review date approaching, patients, families, and clinicians await what could be a landmark moment in treating Hunter syndrome. A successful approval would mark a significant advance in targeting the central nervous system manifestations of rare genetic diseases, bringing a long-sought measure of hope to those affected.

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.